Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phase I/Ib study evaluating safety, efficacy, pharmacokinetics and pharmacodynamics of NIZ985 monotherapy and in combination with an anti-PD-1 agent in patients with advanced solid tumors or lymphoma.

European journal of cancer (Oxford, England : 1990)·2026
Same author

First-in-human study of lomvastomig, a PD-1-TIM-3 bispecific antibody, in patients with advanced and/or metastatic solid tumors.

Journal for immunotherapy of cancer·2026
Same author

Inequities in enrollment across clinical trial phases and the need for a Spanish perspective.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2026
Same author

Integrating antibody-drug conjugates into solid tumor oncology: Current standards and future directions.

Cancer·2026
Same author

Human Absorption, Metabolism, and Excretion (hAME) Mass Balance Studies in Patients With Cancer.

Clinical and translational science·2026
Same author

Quality and safety of research biopsies in oncology clinical trials.

European journal of cancer (Oxford, England : 1990)·2026
Same journal

Explainable incremental-value analysis of apparent diffusion coefficient and arterial spin labeling radiomics for ATRX status prediction in glioblastoma.

Frontiers in oncology·2026
Same journal

Study-level factors associated with hematoma after ultrasound-guided vacuum-assisted breast lesion excision: a systematic review and meta-analysis using a T-P-B framework.

Frontiers in oncology·2026
Same journal

Feasibility and strategy analysis of radiotherapy consolidation following immunotherapy for stage IV esophageal squamous cell carcinoma.

Frontiers in oncology·2026
Same journal

Anastomosing hemangioma of the kidney: a case report.

Frontiers in oncology·2026
Same journal

Machine learning-based prediction of prolonged air leak after uniportal video-assisted thoracic surgery segmentectomy.

Frontiers in oncology·2026
Same journal

Past present and future of radiosensitization in cervical cancer.

Frontiers in oncology·2026
See all related articles

Related Experiment Video

Updated: May 10, 2026

MAME Models for 4D Live-cell Imaging of Tumor: Microenvironment Interactions that Impact Malignant Progression
08:26

MAME Models for 4D Live-cell Imaging of Tumor: Microenvironment Interactions that Impact Malignant Progression

Published on: February 17, 2012

Mapping MAGE-A4 expression in solid cancers for targeted therapies.

Christin Habigt1, Sylvie Rottey2, Iben Spanggaard3

  • 1Roche Pharma Research and Early Development, Early Development Oncology, Roche Innovation Center Munich, Penzberg, Germany.

Frontiers in Oncology
|March 28, 2025
PubMed
Summary
This summary is machine-generated.

Melanoma-associated antigen A4 (MAGE-A4) protein is expressed in 35% of solid tumors. High MAGE-A4 expression was found in adenoid cystic carcinoma, liposarcoma, and ovarian cancers, indicating potential therapeutic targets.

Keywords:
biomarkerclinical trialpatient selectiontarget expressiontranslational analysis

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Cancer-Associated Fibroblasts from Mouse Mammary Tumors as Tools for Molecular and Computational Studies
09:01

Cancer-Associated Fibroblasts from Mouse Mammary Tumors as Tools for Molecular and Computational Studies

Published on: July 3, 2025

Related Experiment Videos

Last Updated: May 10, 2026

MAME Models for 4D Live-cell Imaging of Tumor: Microenvironment Interactions that Impact Malignant Progression
08:26

MAME Models for 4D Live-cell Imaging of Tumor: Microenvironment Interactions that Impact Malignant Progression

Published on: February 17, 2012

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Cancer-Associated Fibroblasts from Mouse Mammary Tumors as Tools for Molecular and Computational Studies
09:01

Cancer-Associated Fibroblasts from Mouse Mammary Tumors as Tools for Molecular and Computational Studies

Published on: July 3, 2025

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Melanoma-associated antigen A4 (MAGE-A4) is a potential target for cancer immunotherapy.
  • Limited data exist on MAGE-A4 protein expression across diverse solid tumors.

Purpose of the Study:

  • To comprehensively assess MAGE-A4 protein expression in various solid cancers.
  • To identify cancer types with high MAGE-A4 prevalence for targeted anti-MAGE-A4 therapies.

Main Methods:

  • Immunohistochemistry (IHC) was used to analyze MAGE-A4 protein expression.
  • 200 patient samples with unresectable/metastatic solid cancers were examined.
  • The cohort was predominantly HLA-A*02:01 positive.

Main Results:

  • MAGE-A4 expression was detected in 35% of the overall cohort (69/200 patients).
  • Highest MAGE-A4 prevalence observed in adenoid cystic carcinoma (82%) and liposarcoma (67%).
  • Significant positivity also noted in ovarian serous/high-grade carcinoma (64%), squamous non-small cell lung cancer (64%), head and neck squamous cell carcinoma (60%), and esophageal cancer (54%).

Conclusions:

  • MAGE-A4 expression varies significantly across different cancer types.
  • Specific cancers show high MAGE-A4 prevalence, suggesting potential for stratified precision medicine approaches.
  • Further research into MAGE-A4's role in oncogenesis and treatment response is warranted.